AGM Statement

DXS International

19/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241219:nGNE9WvPHD&default-theme=true


DXS INTERNATIONAL PLC

(AQSE: DXSP)

DXS AGM 2024 Statement

The Board of DXS International plc (“the Company” or “DXSP”), the AQSE
Growth Market quoted healthcare information and digital clinical decision
support systems provider, is pleased to publish an update on operations and
pipeline progress ahead of its Annual General Meeting ("AGM") taking place
today at Noon at Elm House, Tanshire Park, Shackleford Road. Elstead, Surrey
GU8 6LB.

During the AGM, the Company's CEO, David Immelman, will provide an update on
DXS’s progress. The Company made good progress in 2024 with both Aios SMART
Referrals and ExpertCare, and achieved an NHS price increase.

Aios SMART Referrals

The existing Point of Care solution was replaced with Aios SMART Referrals, a
new cloud based solution. NHS Electronic Referral System integration was
completed, certified and NHS IMI accredited on the NHS G Cloud 14 Procurement
Framework. SMART Referrals are now used for 10% of all referrals in England,
an estimated 1.8 million per annum. Currently 22% of newly established
Integrated Care Boards (ICBs) have some of their practices using Smart
Referrals. These current paid for practices cover approx. 6.5m registered
patients and there is the opportunity to convert the remaining GP practices to
the Smart Referrals solution covering an additional 6.5m patients and to gain
new market share in the remaining 78% of ICBs.

ExpertCare

ExpertCare is a unique Long Term Condition therapeutic management solution.
Currently it has completed 75% or Phase 3 of 4 Phases of an Innovate UK grant
with Health Innovate East, as announced in November 2023, with good results
and York university is conducting an economic impact assessment. The first
commercial sale was secured as announced on 29 October 2024.

Summary

The Company is looking to expand into at least one EU or other territory in
2025 and looks forward to updating the market in due course.

A Presentation that the CEO will deliver during the AGM is available for
download from the Company's website at
https://www.dxs-systems.co.uk/corporate-documents.php

We would like to thank our shareholders and other stakeholders for their
continued support.

The Directors of DXS International plc accept responsibility for this
announcement. This announcement contains information which, prior to its
disclosure, was inside information as stipulated under Regulation 11 of the
Market Abuse (Amendment) (EU Exit) Regulations 2019/310 (as amended).

Contacts:

 David Immelman  DXS International plc  www.dxs-systems.com                      01252 719800   
 AQSE Corporate Broker and Corporate Advisor  Hybridan LLP  Claire Louise Noyce  020 3764 2341  

Notes to Editors

About DXS:

DXS International presents up to date treatment guidelines and
recommendations, from Clinical Commissioning Groups and other trusted NHS
sources, to doctors, nurses and pharmacists in their workflow and during the
patient consultation. This effective clinical decision support ultimately
translates to improved healthcare outcomes delivered more cost effectively and
which should significantly contribute towards the NHS achieving its projected
efficiency savings